real-world results from talquetamab and bispecific antibodies | carolina schinke, md | ash 2023
Published 9 months ago • 572 plays • Length 6:31
Download video MP4
Download video MP3
Similar videos
-
5:29
updates on teclistamab, talquetamab, and carvykti | mark wildgust, phd | ash 2022
-
7:02
talquetamab in pts with relapsed/refractory multiple myeloma: phase 1/2 results from monumental-1
-
8:43
results from monumental-1: first-in-human study of talquetamab in pts with rr multiple myeloma
-
2:02
real-world patient profile and dosing of teclistamab in myeloma | carlyn rose tan, md | ash 2023
-
3:44
ash 2021: new bispecific antibody, talquetamab, to treat multiple myeloma
-
5:20
advancements in myeloma treatment: real world outcomes and quality of life | doris hansen, md
-
17:55
talquetamab | therapies on the horizon
-
55:54
accelerating myeloma research with real world data at the healthtree foundation for multiple myeloma
-
4:59
real-world schedule de-escalation of teclistamab in patients with rrmm | carlyn tan, md | eha 2024
-
4:15
bispecific antibodies in multiple myeloma: teclistamab, talquetamab, and cevostamab
-
10:11
monumental-1: talquetamab in r/r multiple myeloma
-
3:23
what are the results from the endurance trial that compares krd to vrd in newly diagnosed patients?
-
28:40
all about talvey (talquetamab)
-
1:43
real-world outcomes of teclistamab for r/r multiple myeloma
-
4:20
what were the results of the determination trial presented at asco and eha?
-
58:00
know your myeloma immunotherapy: teclistamab and other bispecifics
-
1:14
clinical benefit of teclistamab vs real-world physician’s choice for r/r multiple myeloma
-
0:44
how advances in multiple myeloma research are extending lives
Clip.africa.com - Privacy-policy